Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 57, Issue 5, 1996, Pages 335-340

  Zinzani, P L ^b,c   Baccini, C ^a   Zaccaria, A ^a   Visani, G ^b   Buzzi, M ^b   Morelli, A ^a   Molinari, A L ^a   Salvucci, M ^b   Bendandi, M ^b   Rubboli, D ^a   Gherlinzoni, F ^b   Zanchini, R ^a   Tura, S ^b  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Low grade non Hodgkin's lymphoma; Prognostic factors; sCD23; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; CD23 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 8044224657     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01390.x     Document Type: Article

References (30)

1. REHN S, GLIMELIUS B, STRANG P, et al. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma. Hematol Oncol 1990: 8: 1-12.
2. HOLTE H, DE LANGE DAVIES C, BEISKE K, et al. Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer 1989: 44: 975-980.
3. PEZZELLA F, JONES M, RALFKIAER E, et al. Evaluation of bcl-2 protein expression and 14; 18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 1992: 65: 87-89.
4. LEONARD RCF, HAYWARD RL, PRESCOTT RJ, et al. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Ann Oncol 1991: 2: 655-662.
5. MOTOKURA T, KOBAYASHI Y, FUJITA A, et al. Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. Leuk Lymph 1995: 16: 355-362.
6. RAZIUDDIN S, SHEIKHA A, ABU-ESHY S, AL-JANADI M. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer 1994: 73: 2426-2431.
7. NACHBAUR DM, HEROLD M, MANESCHG A, HUBER H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991: 62: 54-58.
8. KURZROCK R, REDMAN J, CABANILLAS F, et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993: 53: 2118-2122.
9. BARAK V, GINZBURG M, KALICKMAN I, POLLIACK A. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leuk Lymph 1992: 7: 431-438.
10. YEE C, SUTCLIFFE S, MESSNER A, MINDEN MD. Interleukin-6 levels in the plasma of patients with lymphoma. Leuk Lymph 1992: 7: 123-129.
11. WHELAN JS, DAVIS CL, RULE S, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 1991: 64: 120-123.
12. REDMAN JR, CABANILLAS F, VELASQUEZ WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992: 10: 790-794.
13. HOCHSTER HS, KIM K, GREEN MD, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992: 10: 28-32.
14. ZINZANI PL, LAURIA F, RONDELLI D, et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993: 4: 575-578.
15. HIDDEMANN W, UNTERHALT M, POTT C, et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German low-grade non-Hodgkin's lymphoma. Semin Oncol 1993: 20 (Suppl 7): 28-31.
16. MCLAUGHLIN P, HAGEMEISTER FB, SWAN F, et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994: 12: 575-579.
17. COIFFIER B, BARBLER Y, BIENVENU J, et al. Increased plasma tumor necrosis factor alpha (TNF) is correlated with adverse prognostic factors and poor response to treatment in non-Hodgkin's lymphoma (NHL). J Clin Oncol 1992: 11: A1157.
18. JHAVER K, DE A, ADVANI S, NADKARNI J. Production of interleukin-1 and tumor necrosis factor in non-Hodgkin's lymphoma patients. Cancer Immunol Immunother 1991: 34: 123-127.
19. BENGTSSON M, GORDON J, FLORES-ROMO L, et al. B-Cell reconstitution after autologous bone marrow transplantation: increase in seum CD23 ("IgE-Binding Factor") precedes IgE and B-cell regeneration. Blood 1989: 73: 2139-2144.
20. REINISCH W, WILLHEIM M, HILGARTH M, et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994: 12: 2146-2152.
21. STANSFELD AG, DIEBOLD J, KAPANCI Y, et al. Updated Kiel classification for lymphomas. Lancet 1988: i: 292-293.
22. CARBONE PP, KAPLAN HS, MUSSHOFF K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971: 31: 1860-1861.
23. ZINZANI PL, MARTELLI M, STORTI S, et al. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymph 1995: 19: 329-335.
24. ZINZANI PL, BENDANDI M, TURA S. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 1995: 55: 262-266.
25. COX DR. Regression models and life tables. J Roy Stat Soc Seri B 1972: 34: 187-202.
26. INTERNATIONAL NON-HODGKIN'S LYMPHOMA PROGNOSTIC FACTORS PROJECT. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993: 329: 987-994.
27. SARFATI M, BRON D, LAGNEAUX L, et al. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1989: 20: 94-98.
28. CORDINGLEY FT, HOFFBRAND AV, HESLOP HE, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1989: i: 969-971.
29. DIGEL W, STEFANIC M, SCHONIGER W, et al. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia and acute leukemias. Blood 1989: 73: 1242-1246.
30. CHRISTIANSEN I, GIDLOP C, KALKNER KM, et al. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers. Br J Haematol 1996: 92: 639-646.